[1]Gow CH, Hsieh MS, Chen YL, Liu YN, Wu SG, Shih JY. Survival outcomes and prognostic factors of lung cancer patients with the MET exon 14 skipping mutation: A single-center real-world study. Front Oncol. 2023;13:1113696....
1.Juergen Wolf, Edward B. Garon, Harry J.M. Groen, et al.Capmatinib in treatment‑naive MET exon 14-mutated (METex14) advanced non‑small cell lung cancer (aNSCLC): Updated results from GEOMETRY mono-1. 2022 ELCC, Poster 26P.2.Y. Wu, J. Zhao, J. Hu,etc.388P - Capmatinib i...
[3].Gow CH, Hsieh MS, Wu SG, et al. A comprehensive analysis of clinical outcomes in lung cancer patients harboring a MET exon 14 skipping mutation compared to other driver mutations in an East Asian population[J]....
今天分享下2023年6月12日发表在Clinical Lung Cancer针对MET14跳突的《MET exon 14 skipping in NSCLC: A systematic literature review of epidemiology, clinical characteristics, and outcomes》文章(全文翻译版)。 重点结论(内容过长,不想看全文的可直接看结论): 在未选择的肺癌人群中,METex14跳突发生率为2.0%...
[8] Socinski MA, Pennell NA, Davies KD. MET Exon 14 Skipping Mutations in Non-Small-Cell Lung Cancer: An Overview of Biology, Clinical Outcomes, and Testing Considerations. JCO Precis Oncol. 2021 Apr 13;5:PO.20.00516. [9] Liu SY, Gou LY, Li AN et al. The unique characteristics of...
Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping. Cancer Discov. 2015 Aug;5(8):842-9. doi: 10.1158/2159-8290.CD-14-1467. Epub 2015 May 13. Erratum in: Cancer Discov. 2016 Mar;6(3):330. PMID: 25971939;[4] Dril...
[5]. Lu S, Fang J, Li XY, et al. Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: A multicentre, single-arm, open-label, phase 2 study[J]. Lancet Respir Med, 2021, 9(...
本例晚期 NSCLC 患者基因检测发现 MET ex14 跳突,接受赛沃替尼一线治疗获得了持久的生存获益,且患者治疗期间未出现严重不良反应。至最后一次随访时,PFS 超 17 个月,至今患者病情稳定,仍在持续获益中。该病例充分验证了赛沃替尼一线治疗 MET ex14 跳突 NSCLC 的良好疗效和可耐受的安全性。此外,该病例还提示,在...
17. Hiroshi, S., et al., Tepotinib in patients with NSCLC harbouring MET exon 14 skipping: Japanese subset analysis from the Phase II VISION study. Japanese Journal of Clinical Oncology, 2021.18. Alzofon, N. and A. Jimeno, Capmatinib for non-small cell lung cancer. Drugs of today (...
[4]Lu S, Fang J, Li X, et al. Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study[J]. The Lancet Respiratory Medicine, 20...